Demand for retinal treatments is soaring, spurred by rapid growth in elderly populations, increases in diabetes, greater access to medical care in emerging economies, and higher quality-of-life expectations among the aging. New anti-VEGF therapies are successfully treating vision-threatening retinal diseases that, in the recent past, had been largely untreatable. Investigational pharmaceuticals and biologics are making progress in halting the relentless progression of blinding retinal diseases. The retinal treatment paradigm has shifted, and a wealth of new science, business acumen, and bioentrepreneurial activity promise further transformations.
The retinal pharmaceutical market has rapidly evolved into one of the largest segments in the ophthalmic pharmaceutical industry. However, while anti-VEGF therapies have significantly changed the prognosis for many suffering from age-related macular degeneration (AMD), much of the commercial opportunity to date has been constrained by low-cost off-label treatment. Nonetheless, Market Scope expects revenues generated by retinal pharmaceutical sales to climb to $2.8 billion in 2009, while new pipeline products promise significant growth in the coming years.
The more than 50 drug candidates aiming to reshape this market use a variety of new approaches—neuroprotection, kinase inhibition, RNA interference, visual cycle modulation and targeting of the complement cascade—to treat the most devastating retinal diseases such as wet AMD, geographic atrophy, diabetic retinopathy and inherited retinal dystrophies. Although some will fail to meet their goals, others will likely shift the retinal treatment paradigm again. In several years, current market leaders Genentech and Novartis will face a new field of competitors.
Our report on the retinal pharmaceutical market is in its second edition. It is a leading industry source for accurate and relevant information on all aspects of the retinal pharmaceutical market. We cover prevalence and forecasts for retinal diseases and conditions. We discuss therapeutic approaches and mechanisms of action under investigation. We discuss the market dynamics for currently commercialized products and the rich and crowded pipeline of investigational therapies. We review patient-based economic issues and reimbursement and we analyze treatment patterns and trends. We forecast product demand in units and dollars, and we analyze market shares by product category. We also discuss key strategic issues.
In our comprehensive reports, we analyze worldwide markets using the following geographic/economic categories: the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World. This report includes market data for 2008 and we forecast market performance through 2014.
Market Scope’s 2009 Comprehensive Report on the Global Retinal Pharmaceutical Market
is organized into key areas and includes:- Review of Retinal Diseases and Treatments
- Symptoms, Diagnosis and Treatment of AMD
- Diagnosis and Management of Diabetic Retinopathy & Macular Edema
- An Overview of Other Retinal Diseases and Conditions
- Epidemiology of Retinal Disease
- Patient Economics and Reimbursement
- Retinal Specialists & Training
- Current Retinal Pharmaceuticals in the Marketplace
- Mechanisms of Action for Current and Future Therapies
- More than 50 Investigational Therapies in the Pipeline
- Forecast for the Global Retinal Pharmaceutical Market by Region
- 33 Company Profiles and Additional Company Listings
- 40 Color Tables and 32 Color Figures
Our recently published 2009 Comprehensive Report on the Retinal Pharmaceutical Market was released in May 2009. The report is printed in color and spiral bound for easy reading. The price of the report is $4,500. An electronic PDF copy and/or additional paper copies are available for use within your company for an additional $500 and $300, respectively. Order Form
TABLE OF CONTENTS
Scope and Methodology
About the Authors
The Report at a Glance
Executive Summary
Focus on the Most Common Retinal Diseases
Retinal Pharmaceutical Products Market
Leading Competitors
Trends
OVERVIEW OF RETINA & RETINAL DISEASE
Retina
Macula
Fovea and Foveola
Optic Disc and Optic Nerve
Choroid
Vitreous Humor
Pars Plana
The Most Common Retinal Diseases
Inherited Retinopathies
Other Retinal Disorders
Retinal Surgeries
AGE-RELATED MACULAR DEGENERATION
Dry AMD
Geographic Atrophy
GA Investigative Directions
Neovascular AMD
AMD Risk Factors
Symptoms of AMD
Diagnosis and Treatment of AMD
Technologies
Laser Photocoagulation
Pharmaceutical Therapies
DIABETIC RETINOPATHY & DIABETIC MACULAR EDEMA
Diabetes
Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy (PDR)
Diabetic Macular Edema
Increases in Diabetes, DR and DME
DR and DME Risk Factors
Glitazones and DME
Diagnosis and Management
DR and DME treatments
Vitrectomy
Pharmaceuticals
OTHER RETINAL DISEASE & CONDITIONS
Retinitis Pigmentosa & Other Inherited Retinopathies
Treatment
Other Retinal Disease and Conditions
Retinal Artery Occlusion
Retinal Vein Occlusion
Retinoblastoma
Epiretinal Membrane (ERM)
Central Serous Chorioretinopathy (CSCR)
Retinopathy of Prematurity (ROP)
CMV Retinitis
Infectious Inflammatory Chorioretinal Diseases
Retinal Tears, Holes and Detachments
EPIDEMIOLOGY OF RETINAL DISEASE
Epidemiology of AMD
AMD by Category
Epidemiology of Diabetic Retinopathy
Diabetic Retinopathy by Category
Epidemiology of Retinal Holes, Tears, & Detachments
Epidemiology of Inherited & Other Retinal Disease
PATIENT ECONOMICS AND REIMBURSEMENT
Causes of Blindness Globally
Causes of Blindness Shift in Wealthy Nations
Treatment Costs
RETINA SPECIALISTS
Retina Training
The Retina Specialty Worldwide
Services and Reimbursement
Diagnosing and Monitoring
Intravitreal Injections
Laser Photo-Activation
Vitrectomy
Repair of Retinal Detachments
Location of Retinal Services
Retinal Societies
Retina Meetings
RETINAL PHARMACEUTICALS ON THE MARKET
A Brief History
VEGF Inhibitors
Lucentis
Lucentis and Non-AMD Indications
Lucentis’ Safety
The Business of Lucentis
Avastin
Avastin and Non-AMD Ocular Indications
Avastin’s Safety
The Business of Off-label Ophthalmic Avastin
Lucentis/Avastin Controversy
Rift Over Compounding Pharmacies
CATT Compares Lucentis and Avastin
Macugen’s Safety
The Business of Macugen
Treatment Burden of IVT VEGF Inhibition
Photodynamic Therapy
Visudyne Photodynamic Therapy
PDT’s Fluence Rate
Visudyne PDT’s Safety
The Business of Visudyne PDT
Sample Combination Therapy Regimens
Combination Therapy versus Monotherapy
Corticosteroid Safety
Triamcinolone Acetonide
Dexamethasone
Fluocinolone Acetonide
Other Ophthalmic Corticosteroids
Other Pharmaceuticals with Retinal Applications
RETINAL PHARMACEUTICAL PIPELINE
Multiplicity of New Approaches
VEGF Inhibition
Kinase Inhibition
RNA Interference
Antisense Technology
Targeting the Complement Cascade
Neuroprotection
Visual Cycle Modulation
Pharmacologic Vitreolysis
Other Approaches
Sustained Release Approaches
Summary Tables on the Pipeline
FORECAST: GLOBAL RETINAL PHARMA MARKET
The Global Retinal Pharma Market by Region
Forecast for the US Retinal Pharma Market
Forecast for W. Europe’s Retinal Pharma Market
Forecast for Japan’s Retinal Pharma Market
Forecast for OWN’s Retinal Pharma Market Forecast for China’s Retinal Pharma Market
Forecast for India’s Retinal Pharma Market Forecast for Latin America’s Retinal Pharma Market
Forecast for ROW’s Retinal Pharma Market
COMPANY PROFILES
Acucela, Inc.
Alcon, Inc.
Allergan, Inc.
Angstrom Pharmaceuticals, Inc.
Ceregene, Inc.
CoMentis, Inc.
Eli Lilly and Company
Genentech, Inc.
GenVec, Inc.
GlaxoSmithKline plc
iCo Therapeutics
Jerini Ophthalmic, IN.
Lpath, Inc.
MacuCLEAR, Inc.
MacuSight, Inc.
Neurotech Pharmaceuticals, Inc.
Novartis International AG
Novagali Pharma
Opthotech Corporation
OPKO Health, Inc.
Othera Pharmaceuticals Ltd.
Pfizer Inc.
Potentia Pharmaceuticals, Inc.
pSivida Ltd.
QLT Inc.
Quark Pharmaceuticals, Inc.
Regeneron Pharmaceuticals
Silence Therapeutics, plc
Sirion Therapeutics, Inc.
SurModics, Inc.
TargeGen, Inc.
ThromboGenics NV
Vitreoretinal Technologies, Inc.
Other Companies with Pre-Clinical Programs